Persbericht
10 november 2015
7.00 uur CET

Celyad voltooit met succes 30-daagse veiligheidsopvolging van eerste patiëntencohort in fase I-onderzoek naar NKG2D CAR T-cellen

- ***Geen veiligheidsproblemen gemeld 30 dagen na infusie bij eerste patiënt met één dosis NKG2D CAR T-cellen .***
- ***Eerste patiënt van tweede cohort kan nu worden ingeschreven.***
- ***Proef wordt uitgebreid met gerenommeerde onderzoekscentra voor kanker in de VS.***

Mont-Saint-Guibert, België - Celyad (Euronext Brussel en Parijs, en NASDAQ: CYAD), leider in de ontdekking en ontwikkeling van engineered celtherapieën, met klinische programma's voor hart- en vaatziekten en immuno-oncologie, heeft vandaag bekendgemaakt de 30-daagse veiligheidsopvolging te hebben voltooid van de laatste patiënt in de eerste cohort van het klinische fase I-onderzoek naar de veiligheid en de haalbaarheid van haar NKG2D CAR T-celtherapie bij patiënten met acute myeloïde leukemie (AML) of multipel myeloom (MM).

Dit klinische fase I-onderzoek is bedoeld om de infusie van vier escalerende dosissen van NKG2D CAR T-cellen in vier opeenvolgende patiëntcohorten van telkens drie patiënten te beoordelen. Gedurende de opvolgingsperiode van 30 dagen na de infusie van de eerste dosis van NKG2D CAR T-cellen bij de drie patiënten van de eerste cohort (2 AML en 1 MM) werden geen behandelingsgerelateerde veiligheidsproblemen gemeld.

Dr. Christian Homsy, CEO van Celyad, **verklaart**: "Deze gegevens zijn een belangrijke stap in het aantonen van de veiligheid van de NKG2D CAR T-celinfusie bij enkelvoudige dosissen, en geven ons de mogelijkheid om nieuwe patiënten op te nemen in de tweede cohort van deze proef. *Om de opname van deze nieuwe patiënten een duw in de rug te geven en een omvangrijke evaluatie van deze innovatieve aanpak mogelijk te maken, breidt Celyad zijn proefnetwerk uit door samen te werken met gerenommeerde centra voor klinisch onderzoek in de VS.*

"Deze resultaten geven ons, samen met de resultaten van de eerste patiënt na de opvolgingsperiode van 30 dagen in juni en de recente voltooiing van belangrijke mijlpalen in de programma's C-Cure® en NKG2D CAR T-cellen, extra vertrouwen dat we onze doelstellingen op het vlak van klinische ontwikkeling voor onze nieuwe pijplijn kunnen bereiken."

Dr. Frédéric Lehmann, Vicepresident immuno-oncologie van Celyad: *"Het is de eerste keer dat ons technologieplatform, dat Celyad in januari 2015 heeft aankocht, is getest op mensen. De veiligheidsresultaten waar we tot nu toe over beschikken geven ons vertrouwen in de*

toekomst van het NKG2D CAR T-celprogramma en we vinden dat we goed geplaatst zijn om onze klinische programma's voor immuno-oncologie volgens plan voort te zetten."

De volledige gegevens van het klinische fase I-onderzoek op 12 patiënten worden midden 2016 verwacht. Het onderzoek is opgezet om de veiligheid en de haalbaarheid van behandeling met NKG2D CAR T-cellen als primaire eindpunten te beoordelen, met als secundaire eindpunten onder meer de klinische werkzaamheid.

END

Voor meer informatie kan u contact opnemen met:

Voor Europa : Consilium Strategic Communications
Amber Fennell, **Chris Gardner**, **Chris Welsh**,en **Laura Thornton -** T: +44 (0)20 3709 5700 – celyad@consilium-comms.com

Voor de VS. : The Ruth Group
Lee Roth (Investeerders) en **Kirsten Thomas** (Media) - T: +1 646 536 7012 / 7014 - celyad@theruthgroup.com

Voor Frankrijk : NewCap
Pierre Laurent en **Nicolas Mérigeau -** T: + 33(0)1 44 71 94 94 - celyad@newcap.fr

Celyad
Christian Homsy, CEO en **Patrick Jeanmart**, CFO : T: +32 (0)10 39 41 00 investors@celyad.com

Om u in te schrijven op de nieuwsbrief van Celyad, ga naarwww.celyad.com
Volg ons op TwitterTwitter @CelyadSA en op LinkedIn

About CAR-NKG2D

Celyad's lead immuno-oncology product candidate, CAR-NKG2D, is a chimeric antigen receptor (CAR) T-Cell autologous therapy to treat cancer. The CAR technology developed by Celyad uses human natural killer cell (NK cell) receptors which, unlike traditional CAR technologies such as those targeting the CD19 antigen, has the potential to target ligands present on a broad range of solid tumors and blood cancers.

The research underlying this technology was originally conducted by Dartmouth College Professor Charles Sentman, and has been published in numerous peer-reviewed publications such as Journal of Immunology in 2009, Cancer Research in 2006, and Blood in 2005. CAR-NKG2D has an active Investigational New Drug (IND) application with the FDA for a Phase I clinical trial in certain hematologic cancers.

CAR-NKG2D entered a Phase I clinical trial in April 2015. The full data readout from the Phase I dose escalation trial is expected in mid-2016. The trial is designed to assess the safety and feasibility of NKG2D CAR T-cell in certain acute myeloid leukemia and multiple myeloma patients as primary endpoints, with secondary endpoints including clinical efficacy.

About Celyad

Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiology and oncology. Celyad is developing its lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure, and has completed enrollment of a Phase III trial in Europe and Israel. In addition, the Company is developing a novel portfolio of CAR T-cell therapies that utilize human Natural Killer cell receptors for the treatment of numerous blood and solid cancers. Its lead oncology product candidate, NKG2D CAR T-cell, entered a Phase I clinical trial in April 2015.

Celyad's ordinary shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CYAD and Celyad's American Depositary Shares are listed on the NASDAQ Global Market under the ticker symbol CYAD.

To learn more about Celyad, please visit www.celyad.com

Forward looking statements

In addition to historical facts or statements of current condition, this press release contains forward-looking statements, including statements about the potential safety and feasibility of NKG2D CAR T-cell therapy and C-Cure and the clinical potential of the Company's technology platform generally and the timing of future clinical trials, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements.

In particular it should be noted that the 30-day safety data described in the release are preliminary in nature and thePahse 1 trial is not completed. There is limited data concerning safety and feasibility of NKG2D CAR T-cell therapy. These data may not continue for these subjects or be repeated or observed in ongoing or future studies involving our NKG2D CAR T-cell therapy, C-Cure or other product canditates. It is possible that safety issues or adverse events may arise in the future.

These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including risks associated with conducting clinical trials; the risk that safety, bioactivity, feasibility and/or efficacy demonstrated in earlier clinical or pre-clinical studies may not be replicated in subsequent studies; risk associated with the timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure® and Phase I clinical trial for NKG2D CAR T-cell; risks associated with the satisfaction of regulatory and other requirements; risks associated with the actions of regulatory bodies and other governmental authorities; risks associated with obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties; risks associated with competition from others developing products for similar uses; risks associated with our ability to manage operating expenses;, and risks associated with our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and business initiatives. A further list and description of these risks, uncertainties and other risks can be found in the Company's Securities and Exchange Commission filings and reports, including in the Company's prospectus filed with the SEC on June 19, 2015 and future filings and reports by the Company. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. The Company expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.